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The UK Standardisation of Breast Radiotherapy (START) 
Trial A of radiotherapy hypofractionation for treatment of 
early breast cancer: a randomised trial
The START Trialists’ Group*
Summary
Background The international standard radiotherapy schedule for breast cancer treatment delivers a high total dose in 
25 small daily doses (fractions). However, a lower total dose delivered in fewer, larger fractions (hypofractionation) is 
hypothesised to be at least as safe and eﬀ ective as the standard treatment. We tested two dose levels of a 13-fraction 
schedule against the standard regimen with the aim of measuring the sensitivity of normal and malignant tissues to 
fraction size.
Methods Between 1998 and 2002, 2236 women with early breast cancer (pT1-3a pN0-1 M0) at 17 centres in the UK 
were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2·0 Gy versus 41·6 Gy or 39 Gy in 
13 fractions of 3·2 Gy or 3·0 Gy over 5 weeks. Women were eligible if they were aged over 18 years, did not have an 
immediate surgical reconstruction, and were available for follow-up. Randomisation method was computer generated 
and was not blinded. The protocol-speciﬁ ed principal endpoints were local-regional tumour relapse, deﬁ ned as 
reappearance of cancer at irradiated sites, late normal tissue eﬀ ects, and quality of life. Analysis was by intention to treat. 
This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779.
Findings 749 women were assigned to the 50 Gy group, 750 to the 41·6 Gy group, and 737 to the 39 Gy group. After a 
median follow up of 5·1 years (IQR 4·4–6·0) the rate of local-regional tumour relapse at 5 years was 3·6% (95% CI 
2·2–5·1) after 50 Gy, 3·5% (95% CI 2·1–4·3) after 41·6 Gy, and 5·2% (95% CI 3·5–6·9) after 39 Gy. The estimated 
absolute diﬀ erences in 5-year local-regional relapse rates compared with 50 Gy were 0·2% (95% CI –1·3% to 2·6%) 
after 41·6 Gy and 0·9% (95% CI –0·8% to 3·7%) after 39 Gy. Photographic and patient self-assessments suggested 
lower rates of late adverse eﬀ ects after 39 Gy than with 50 Gy, with an HR for late change in breast appearance 
(photographic) of 0·69 (95% CI 0·52–0·91, p=0·01). From a planned meta-analysis with the pilot trial, the adjusted 
estimates of α/β value for tumour control was 4·6 Gy (95% CI 1·1–8·1) and for late change in breast appearance 
(photographic) was 3·4 Gy (95% CI 2·3–4·5). 
Interpretation The data are consistent with the hypothesis that breast cancer and the dose-limiting normal tissues 
respond similarly to change in radiotherapy fraction size. 41·6 Gy in 13 fractions was similar to the control regimen 
of 50 Gy in 25 fractions in terms of local-regional tumour control and late normal tissue eﬀ ects, a result consistent 
with the result of START Trial B. A lower total dose in a smaller number of fractions could oﬀ er similar rates of 
tumour control and normal tissue damage as the international standard fractionation schedule of 50 Gy in 
25 fractions.
Introduction
In women with early breast cancer prescribed 
radiotherapy after tumour excision or mastectomy, the 
eﬀ ective dose of radiation is adjusted to balance the risk 
of local cancer recurrence against the risk of harmful 
eﬀ ects on healthy tissues. Radiotherapy reduces the risk 
of local relapse by about 70% and reduces breast cancer 
mortality.1 Such treatment is oﬀ ered to nearly all patients 
after local tumour excision and to selected patients after 
mastectomy. The most frequently used schedule 
worldwide is 50 Gy, delivered in 25 fractions of 2·0 Gy 
over 5 weeks. This schedule has evolved pragmatically, 
and is based on an assumption that a high total dose 
delivered in small fractions of 2·0 Gy keeps the amount 
of normal tissue damage to a minimum while gaining 
the maximum level of tumour control. This perception 
was strengthened when early studies of hypofractionation, 
which did not use adequate reductions in total dose, 
reported unacceptably high rates of normal tissue 
injury.2
Normal and malignant tissues vary in their responses 
to radiotherapy fraction size, termed fractionation 
sensitivity. Responses are described by a model in 
which the sensitivity (measured by the degree of tissue 
damage for normal tissues, and tumour recurrence 
rates for malignant tumours) to fraction size is 
represented by the ratio of two constants α and β.3 The 
lower the ratio of α to β (expressed in Gy), the greater 
the eﬀ ect on normal and malignant tissues of changes 
in fraction size. Healthy tissues of the breast and 
ribcage are sensitive to fraction size, with α/β values 
5 Gy or less,4 so small changes in fraction size can 
produce relatively large changes in the eﬀ ects of 
radiotherapy on these tissues. This sensitivity is typical 
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of so-called late-reacting normal tissues that take 
months or years to develop atrophy or ﬁ brosis after 
radiotherapy. By contrast, squamous carcinomas of the 
lung and the head and neck area have high α/β values 
(≥10 Gy), indicating low sensitivity to fraction size. In 
head and neck cancer, radiotherapy delivered in small 
fractions (≤2·0 Gy) to a high total dose spares 
late-responding normal tissues relative to tumour.5 
Breast cancer has previously been thought to be 
insensitive to fraction size and best treated with 
fractions of 2·0 Gy or less. However, some trials have 
tested the hypothesis that breast cancer is as sensitive 
to fraction size as the normal tissues of the breast and 
underlying rib cage.6–8 If conﬁ rmed, these ﬁ ndings 
could indicate that small fraction sizes of 2·0 Gy or 
lower oﬀ er no therapeutic advantage, and that a more 
eﬀ ective strategy would be to deliver fewer, larger 
fractions to a lower total dose.
Between 1986 and 1998 at the Royal Marsden Hospital 
(RMH) and Gloucestershire Oncology Centre (GOC) in 
the UK, 1410 patients prescribed whole breast radiotherapy 
after breast conservation surgery were randomised to 
50 Gy in 25 fractions or to two dose levels of a 13-fraction 
regimen over 5 weeks—39 Gy in 3·0 Gy fractions and 
42·9 Gy in 3·3 Gy fractions.7,8 The primary endpoint was 
late normal tissue eﬀ ects, with local tumour control as a 
secondary endpoint, and the results were consistent with 
breast cancer having a similar sensitivity to fraction size as 
the late-reacting healthy tissues. Based on this pilot study, 
the Standardisation of Breast Radiotherapy (START) Trials 
were initiated by the UK Coordinating Committee for 
Cancer Research (now National Cancer Research Institute) 
to extend the testing of radiotherapy schedules using 
fraction sizes larger than 2·0 Gy , in terms of local-regional 
tumour control, normal tissue eﬀ ects, quality of life, and 
health economic consequences. The initiative consisted of 
two parallel trials, START Trial A and START Trial B. Trial 
A maintained the explanatory design of the RMH/GOC 
trial, with a reduction in one of the test group doses from 
42·9 Gy in 3·3 Gy fractions to 41·6 Gy in 3·2 Gy fractions, 
following advice from the Independent Data Monitoring 
Committee. This change was recommended because the 
42·9 Gy in 3·3 Gy regimen seemed to have slightly more 
late normal tissue eﬀ ects than 50 Gy in 2·0 Gy fractions. 
The trial was designed to allow interpolation between two 
13-fraction regimens in order to identify the schedule 
equivalent to 50 Gy in 25 fractions in terms of late normal 
tissue eﬀ ects, and to compare local tumour control at this 
test-dose level. The protocol-speciﬁ ed intent was to 
combine the datasets of the pilot trial and START Trial A 
under guidance of the Independent Data Monitoring 
Committee to more precisely estimate the fractionation 
sensitivity of breast cancer. By contrast, START Trial B9 
was a more pragmatic trial that compared a commonly 
used schedule in the UK (40 Gy in 15 fractions in 3 weeks) 
with a control group of 50 Gy in 25 fractions over 5 weeks. 
This paper presents the results of Trial A.
Methods
Participation was open to all UK centres that provided 
radiotherapy treatment to patients with early breast 
Fractionation schedule Total n=2236 (%)
50 Gy in 
25 fractions
n=749 (%)
41·6 Gy in 
13 fractions
n=750 (%)
39 Gy in 
13 fractions
n=737 (%)
Age (years)
20–29 5 (0·7) 4 (0·5) 3 (0·4) 12 (0·5)
30–39 38 (5·1) 40 (5·3) 38 (5·2) 116 (5·2)
40–49 116 (15·5) 136 (18·1) 129 (17·5) 381 (17·0)
50–59 280 (37·4) 283 (37·7) 286 (38·8) 849 (38·0)
60–69 215 (28·7) 192 (25·6) 194 (26·3) 601 (26·9)
70–79 87 (11·6) 85 (11·3) 78 (10·6) 250 (11·2)
80– 8 (1·1) 10 (1·3) 9 (1·2) 27 (1·2)
Mean (SD) 57·6 (10·5) 57·0 (10·7) 57·1 (10·5) 57·2 (10·6)
Time from surgery to 
randomisation (weeks); median 
(IQR) [range]
8·8 (5·3–20·8)
[0·4–71·3]
9·4 (5·9–20·2)
[1·0–50·3]
9·3 (5·4–21·1)
[1·1–53·6]
9·1 (5·4–20·7)
[0·4–71·3]
Primary surgery
Breast conserving surgery 631 (84·2) 641 (85·5) 628 (85·2) 1900 (85·0)
Mastectomy 118 (15·8) 109 (14·5) 109 (14·8) 336 (15·0)
Histological type
Invasive ductal 581 (77·6) 585 (78·0) 584 (79·2) 1750 (78·3)
Invasive lobular 88 (11·7) 95 (12·7) 83 (11·3) 266 (11·9)
Mixed ductal/lobular 21 (2·8) 17 (2·3) 17 (2·3) 55 (2·5)
Other 57 (7·6) 51 (6·8) 52 (7·1) 160 (7·2)
Not known 2 (0·3) 2 (0·3) 1 (0·1) 5 (0·2)
Pathological node status
Positive 222 (29·6) 197 (26·3) 224 (30·4) 643 (28·8)
Negative 514 (68·6) 536 (71·5) 497 (67·4) 1547 (69·2)
Not known (no axillary surgery) 12 (1·6) 17 (2·3) 15 (2·0) 44 (2·0)
Not known (missing data) 1 (0·1) 0 (0·0) 1 (0·2) 2 (0·1)
Tumour size (cm)
<1 24 (3·2) 26 (3·5) 24 (3·3) 74 (3·3)
1– 362 (48·3) 347 (46·3) 355 (48·2) 1064 (47·6)
2– 202 (27·0) 203 (27·1) 198 (26·9) 603 (27·0)
3– 156 (20·8) 169 (22·5) 157 (21·3) 482 (21·6)
Not known 5 (0·7) 5 (0·7) 3 (0·3) 13 (0·6)
Tumour grade
1 157 (21·0) 150 (20·0) 149 (20·2) 456 (20·4)
2 369 (49·3) 379 (50·5) 368 (49·9) 1116 (49·9)
3 212 (28·3) 207 (27·6) 210 (28·5) 629 (28·1)
Not known (not applicable)* 11 (1·5) 10 (1·3) 6 (0·8) 27 (1·2)
Not known 0 (0·0) 4 (0·6) 4 (0·5) 8 (0·4)
Adjuvant therapy
None 52 (6·9) 53 (7·1) 67 (9·1) 172 (7·7)
Tamoxifen/no chemotherapy 416 (55·5) 418 (55·7) 376 (51·0) 1210 (54·1)
Chemotherapy/no tamoxifen 86 (11·5) 77 (10·3) 82 (11·1) 245 (11·0)
Tamoxifen+chemotherapy 173 (23·1) 187 (25·0) 188 (25·5) 548 (24·5)
Other endocrine therapy† 17 (2·3) 13 (1·7) 17 (2·3) 47 (2·1)
Not known 5 ( 0·7) 2 ( 0·2) 7 ( 0·9) 14 ( 0·6)
(Continues on next page)
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cancer. With START Trials A and B running in parallel, 
centres chose to participate in either Trial A (17 centres) 
or B (23 centres). Due to earlier completion of recruitment 
in Trial B, those centres were invited to join Trial A after 
accrual to Trial B was complete.
Patients
Women with operable invasive breast cancer 
(International Union Against Cancer pT1-3a pN0-1 M0) 
requiring radiotherapy after surgery (breast-conserving 
surgery or mastectomy, with clear tumour margins 
≥1 mm) were eligible for the trial if they were aged over 
18 years, did not have an immediate surgical 
reconstruction, and were available for follow-up. Unlike 
the pilot study, which had normal tissue eﬀ ects as the 
primary endpoint, mastectomy patients were included in 
Trial A, since tumour control was one of the principal 
endpoints. Patients from 13 centres participating in 
Trial A were also recruited into the quality of life and 
health economics studies (health economics data not 
reported here, baseline quality of life data have been 
published elsewhere10). 13 centres recruited patients who 
had breast-conserving surgery into the photographic 
assessment substudy (12 centres were in both the quality 
of life and photographic studies). Patients from 12 centres 
also consented to donate a 20 mL blood sample for the 
study and to complete an associated family history 
questionnaire (substudy not reported here). The START 
Trials were approved by the South Thames Multi-Research 
Ethics Committee in September, 1998, and by the local 
ethics committees of all participating centres. Written 
informed consent was obtained for all patients.
Procedures
START Trial A patients were randomised to either 50 Gy 
in 25 fractions (control group) or 41·6 Gy in 13 fractions 
or 39 Gy in 13 fractions (experimental schedules). All 
regimens were administered over 5 weeks to eliminate 
treatment time as a variable. This treatment involved ﬁ ve 
fractions per week in the control group and ﬁ ve treatments 
per fortnight (Monday, Wednesday, Friday one week, 
Tuesday and Thursday the next week) in each of the two 
experimental schedules.
Randomisation was arranged via telephone at the 
Clinical Trials and Statistics Unit at the Institute of 
Cancer Research (ICR-CTSU), Sutton, UK, where patient 
details were recorded and treatment was allocated. 
Randomisation was not blinded. Computer-generated 
random permuted blocks were used as the method of 
allocation, with patients stratiﬁ ed by hospital, type of 
surgery (breast conserving surgery or mastectomy), and 
intention to give a tumour bed boost dose or not. Use of 
adjuvant systemic treatment was recorded, with a 
requirement of at least a 2-week gap between exposure to 
chemotherapy and radiotherapy.
Patients lay in a supine treatment position. The 
planning target volume was deﬁ ned as the whole breast 
with a 1 cm margin to palpable breast tissue; where 
regional radiotherapy was indicated, the planning target 
volume was supraclavicular nodes with or without 
axillary chain with a 1 cm margin. The decision to give 
regional radiotherapy was made before randomisation 
and was only used in 14% of patients (table 1). In two 
patients prescribed radiotherapy to the breast and 
supraclavicular fossa and randomised to the 41·6 Gy 
schedule, the total dose administered to the 
supraclavicular fossa was reduced to 39 Gy because of 
the sensitivity of brachial plexus to fraction size. Most 
patients were treated with 6 MV x-rays, although 
treatment with higher energies or cobalt γ-rays was 
allowed after discussion with the START Trial 
radiotherapy quality assurance team. Planning protocols 
were speciﬁ ed at the time of notiﬁ cation of participation 
into the study and had to conform to the minimum 
quality criteria described in the START Trial A protocol. 
Planning protocols varied slightly between centres, but 
within each centre they were identical in each 
fractionation group. Doses were prescribed to 
international reference points.11 Departments were 
required to have a protocol specifying whether patients 
who had breast-conserving surgery would receive a boost 
to the tumour bed, and to use an electron ﬁ eld of 
appropriate energy to deliver 10 Gy in ﬁ ve daily fractions 
to the 100% isodose after initial radiotherapy.
Fractionation schedule Total n=2236 (%)
50 Gy in 
25 fractions
n=749 (%)
41·6 Gy in 
13 fractions
n=750 (%)
39 Gy in 
13 fractions
n=737 (%)
(Continued from previous page)
Lymphatic treatment
None 8 (1·1) 14 (1·9) 13 (1·8) 35 (1·6)
Surgery/no radiotherapy 610 (81·4) 636 (84·8) 620 (84·1) 1866 (83·5)
Radiotherapy/no surgery 3 (0·4) 4 (0·5) 2 (0·3) 9 (0·4)
Surgery+radiotherapy 119 (15·9) 95 (12·7) 95 (12·9) 309 (13·8)
Not known 9 (1·2) 1 (0·1) 7 (0·9) 17 (0·8)
Boost (BCS patients only) n=631 n=641 n=628 n=1900
Yes 381 (60·4) 391 (61·0) 380 (60·5) 1152 (60·6)
No 242 (38·3) 249 (38·8) 241 (38·4) 732 (38·5)
Not known 8 (1·3) 1 (0·2) 7 (1·1) 16 (0·8) 
From baseline photographs n=413 n=421 n=416 n=1250
Breast size
Small 43 (10·4) 47 (11·2) 41 (9·9) 131 (10·5)
Medium 294 (71·2) 324 (77·0) 322 (77·4) 940 (75·2)
Large 76 (18·4) 50 (11·9) 53 (12·7) 179 (14·3)
Surgical deﬁ cit
Small 232 (56·2) 235 (55·8) 249 (59·9) 716 (57·3)
Medium 142 (34·4) 146 (34·7) 132 (31·7) 420 (33·6)
Large 39 (9·4) 40 (9·5) 35 (8·4) 114 (9·1)
BCS=breast-conserving surgery. *Lobular and other histological types. †Other endocrine therapies include 
combinations of tamoxifen/anastrozole/letrozole/exemestane/goserelin, mostly within randomised trials.
Table 1: Demographic and clinical characteristics at randomisation of the 2236 patients in START Trial A
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All centres submitted details of the standard 
radiotherapy technique, after which a visit by the quality 
assurance team checked dosimetric measurements in 
a 2D and 3D breast phantom, including the junction 
region between supraclavicular fossa and tangential 
breast or chest wall ﬁ elds.12–15 The mean diﬀ erence 
between prescribed and measured dose in a phantom 
was 2·1%. Additionally, a third of the radiotherapy 
treatment plans were collected and analysed by the 
quality assurance team to ensure compliance with the 
protocol in terms of prescription point, dose 
homogeneity, and lung depth. A random sample of 
patients had in-vivo thermoluminescent dosimeter 
measurements taken.16–18 The protocol allowed for a dose 
variation (in the planning target volume) between 95% 
and 105% of that at the reference point on the central 
axis. Lung depth data was obtained by the radiotherapy 
quality assurance programme, and analysis indicated 
that most patients had less than 2 cm of lung within the 
treatment volume. These results conﬁ rmed a good 
compliance with the technical aspects of the trial 
protocol.
The principal endpoints speciﬁ ed in the protocol were 
local-regional relapse, normal tissue eﬀ ects, and quality 
of life. Local-regional tumour relapse was deﬁ ned as local 
relapse in breast or chest wall, and regional relapse in 
ipsilateral axilla or supraclavicular fossa if it had been 
within an irradiated target volume. Any ipsilateral 
regional relapse outside the radiotherapy target volume 
was excluded from the analysis of local-regional relapse. 
Normal tissue eﬀ ects in the breast, arm, and shoulder 
were assessed by photographic comparison with baseline, 
patient self-reported assessments, and physician 
assessments. Other endpoints were disease-free and 
overall survival, second primary cancers, and health 
economic consequences. Disease-free survival was 
deﬁ ned as time to any breast cancer-related event 
(local-regional or distant relapse, contralateral breast 
cancer, or death from breast cancer). Data relating to ﬁ ve 
key breast normal tissue eﬀ ects from the patient quality 
of life self-assessments are presented here. Separate 
papers will present the full analysis of all self-assessments 
and physician assessments of normal tissue eﬀ ects, and 
of quality of life. Cases of ischaemic heart disease, 
symptomatic rib fracture, and symptomatic lung ﬁ brosis 
were recorded during follow-up; incidence with and 
without conﬁ rmation of diagnosis (eg, using imaging 
and further investigation) was included. Brachial 
plexopathy was reported if damage to the brachial plexus 
was suspected and the patient had symptoms of pain, 
parasthesia, numbness, or other sensory symptoms 
(graded on a 4-point scale). Suspected cases of brachial 
plexopathy were subject to conﬁ rmation by neuro-
physiological assessment and MRI.
Patients were reviewed every year for tumour relapse 
and radiotherapy-induced normal tissue eﬀ ects. Clinical 
data were recorded on pre-printed case report forms and 
sent to the coordinating clinical trials oﬃ  ce at the ICR-
CTSU, Sutton, UK. Photographs were taken at baseline 
(post-surgery and pre-radiotherapy) and then at 2 and 
5 years to assess changes to the breast based on change 
in size, shrinkage, and shape, and scored on a 3-point 
graded scale. Changes in breast appearance (photographic) 
were scored by three observers blind to patient identity, 
treatment allocation, and year of follow-up, and a ﬁ nal 
agreed score reached by consensus. The assessment of 
change in breast appearance from photographs was fully 
validated in the pilot study.7 Breast size and surgical 
deﬁ cit were both deﬁ ned from the baseline photographs 
by the same three observers applying 3-point graded 
scales. Quality of life data were obtained using 
standardised questionnaires19–22 at baseline and at 
6 months, 1, 2, and 5 years. Post-baseline quality of life 
questionnaires included an additional four protocol-
speciﬁ c items relating to changes in the aﬀ ected breast 
after radiotherapy (skin changes in the area of the aﬀ ected 
breast, overall change in breast appearance, ﬁ rmness to 
touch of the aﬀ ected breast, and reduction in size of the 
aﬀ ected breast). Of these four items, patients who had 
had mastectomy only rated change in skin appearance 
after radiotherapy. Details of the quality of life study 
protocol and baseline data have been published 
elsewhere.10
The trial was coordinated by the ICR-CTSU, Sutton, UK. 
The trial was overseen by a Steering Committee of several 
749 allocated 50 Gy in
25 fractions over 5 weeks
750 allocated 41·6 Gy in
13 fractions over 5 weeks
737 allocated 39 Gy in
13 fractions over 5 weeks
735 received allocated treatment*
8 refused allocated treatment
1 whole breast treatment
not given
1 recurrence found
3 severe skin reactions,
treatment stopped after
23 fractions 
1 withdrew after randomisation 
due to depression
741 received allocated treatment*
4 given non-allocated treatment
1 whole breast treatment
not given
1 withdrew after randomisation 
(given 50 Gy)
1 continual wound infection
(given 50 Gy)
1 treatment delayed for 18 days
1 found to have metastases
requiring further surgery,
so radiotherapy suspended
731 received allocated treatment*
4 given non-allocated treatment
1 refused to complete
treatment—iridium implant
given
1 withdrew after randomisation 
(given 40 Gy in 20 fractions )
5 with baseline data only
3 withdrew consent to
follow-up after randomisation
2 moved
2 with baseline data only
1 moved
1 unknown
2 with baseline data only
   2 withdrew consent to
follow-up after randomisation
749 included in analysis 750 included in analysis 737 included in analysis 
2236 patients randomised
Figure 1: Trial proﬁ le for START Trial A
*Only major treatment deviations listed. Minor deviations due to public holidays, machine service days, and 
machine breakdowns not included.
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independent experts joined by members of the ICR-CTSU, 
START Trial Management Group, and representatives of 
the funding bodies (as observers). The Trial Management 
Group was responsible for the day-to-day management of 
the trial, and the emerging safety and eﬃ  cacy data was 
reviewed regularly by the Independent Data Monitoring 
Committee. Central statistical monitoring of data was 
done by ICR-CTSU, supplemented by selected on-site 
source document veriﬁ cation.
Statistical analysis
The sample size was estimated with the intent of 
measuring diﬀ erences in local-regional tumour relapse 
between each 13-fraction schedule and the control 
group. A 5-year local-regional tumour relapse rate 
of 10% in the 50 Gy group was predicted, based on the 
RMH/GOC pilot trial.8 A target sample size of 
2000 patients was deﬁ ned in Trial A to provide 
80% power to detect a diﬀ erence of 5% in the 
local-regional relapse rate between the control group 
and each test group (two-sided α=0·05). With this 
sample size, the estimated standard error for the 
diﬀ erence between schedules was 1·64%.
Survival analysis methods were used to compare rates 
of each endpoint between the fractionation schedules. 
Length of follow-up was calculated as time from 
randomisation until time of ﬁ rst event or last follow-up 
assessment, whichever occurred ﬁ rst. Patients were still 
evaluable for local-regional relapse after distant relapse, 
but were censored at date of death. For the photographic 
endpoint, patients were no longer evaluable for change 
in breast appearance after local-regional relapse. 
Kaplan-Meier estimates of 5-year relapse rates, rates of 
normal tissue eﬀ ects, rates of any breast-cancer related 
event, and mortality rates were calculated (with 95% CIs). 
For the patient quality of life self-assessments of normal 
tissue eﬀ ects an event was deﬁ ned as the ﬁ rst occurrence 
of a moderate or marked symptom (graded “quite a bit” 
or “very much”). The scores from the photographic 
assessments of change in breast appearance at 2 and 
5 years were dichotomised as none versus mild or marked 
change, and the ﬁ rst occurrence of such a change was 
taken as the endpoint for the survival analysis. There 
were too few patients with marked change in breast 
appearance (photographic) to be able to analyse this 
category separately.
The Wald test was used to compare between pairs of 
fractionation schedules. Crude hazard ratios (with 95% CIs) 
comparing fractionation schedules for each endpoint were 
obtained from Cox proportional hazards regression 
models. The proportionality assumption of the Cox model 
was tested using Schoenfeld residuals and was found to be 
valid for all of the analyses. Since point estimates of 
diﬀ erences in event rates can, by chance, be atypical of the 
overall pattern of diﬀ erences between schedules, estimates 
of the absolute diﬀ erence in 5-year event rates taking the 
whole range of observation times into account were 
obtained by applying the hazard ratios obtained from the 
Cox model to the Kaplan-Meier estimate of the rate in the 
50 Gy control group.23 Both one-sided and two-sided 
95% CIs were calculated for the absolute diﬀ erence in 
local-regional relapse rates at 5 years, since the upper limit 
is of greater clinical interest, in view of concern about a 
possible excess risk caused by hypofractionated schedules. 
Kaplan-Meier survival curves and Nelson-Aalen cumulative 
hazard functions were plotted according to fractionation 
schedule. Plots were censored at the median length of 
follow-up (rounded to nearest year).
A direct estimate of the α/β value for breast cancer was 
obtained by ﬁ tting a Cox proportional hazards regression 
model containing terms for total dose, and total dose 
multiplied by dose per fraction, to the local-regional 
relapse data. Similarly, an estimate of the α/β value for 
dose-limiting normal tissues was obtained by ﬁ tting the 
same regression model to the photographic data for 
change in breast appearance. In each case, the α/β ratio 
was calculated by dividing the two parameter estimates 
(estimate for total dose/estimate for total dose × dose per 
fraction). Where appropriate, the Cox models included 
covariates associated with relapse and late normal tissue 
eﬀ ects, so the resulting α/β value estimates (and 95% CI) 
were adjusted for prognostic factors. Approximate 
95% CI for the α/β value estimates were calculated using 
a Taylor series expansion for the covariance of a ratio of 
two random variables. Lower limits of CIs for the 
Events/total (%) Estimated % with event 
by 5 years (95% CI)
Crude hazard ratio 
(95% CI)
Wald test 
p value*
Local relapse†
50 Gy 25/749 (3·3) 3·2 (1·9–4·6) 1 –
41·6 Gy 28/750 (3·7) 3·2 (1·9–4·5) 1·09 (0·64–1·88) 0·74
39 Gy 31/737 (4·2) 4·6 (3·0–6·2) 1·25 (0·74–2·12) 0·40
Local-regional relapse
50 Gy 28/749 (3·7) 3·6 (2·2–5·1) 1 –
41·6 Gy 30/750 (4·0) 3·5 (2·1–4·3) 1·05 (0·63–1·75) 0·86
39 Gy 35/737 (4·7) 5·2 (3·5–6·9) 1·26 (0·77–2·08) 0·35
Distant relapse
50 Gy 73/749 (9·7) 9·8 (7·5–12·0) 1 –
41·6 Gy 69/750 (9·2) 9·5 (7·3–11·7) 0·92 (0·66–1·28) 0·64
39 Gy 93/737 (12·6) 11·9 (9·5–14·4) 1·29 (0·95–1·76) 0·10
Any breast cancer-related event‡
50 Gy 102/749 (13·6) 13·6 (11·0–16·2) 1 –
41·6 Gy 91/750 (12·1) 12·0 (9·6–14·5) 0·87 (0·65–1·15) 0·33
39 Gy 115/737 (15·6) 15·2 (12·5–17·9) 1·14 (0·87–1·49) 0·33
All-cause mortality
50 Gy 84/749 (11·2) 11·1 (8·7–13·4) 1 –
41·6 Gy 89/750 (11·9) 11·3 (8·9–13·7) 1·04 (0·77–1·40) 0·81
39 Gy 83/737 (11·3) 10·7 (8·3–13·1) 1·00 (0·74–1·36) 0·99
*p value from Wald test comparing each schedule with 50 Gy. †Local relapse deﬁ ned as ipsilateral local tumour relapse 
in breast parenchyma / breast skin / chest wall skin. ‡Breast cancer-related events: local, regional, or distant relapse, 
breast cancer death, contralateral breast cancer (disease-free survival).
Table 2: Survival analyses of relapse and mortality according to fractionation schedule in START Trial A
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α/β ratios were truncated at zero when the calculated 
limit was negative.
The protocol speciﬁ ed that the START Trial A data would 
be combined with the RMH/GOC pilot study data8 to 
obtain a combined estimate of the adjusted α/β values for 
breast cancer and for normal tissues. In view of the 
diﬀ erences between the trials in terms of absolute rates of 
local relapse and patient characteristics, a meta-analysis 
was subsequently considered more appropriate, on the 
advice of the Independent Data Monitoring Committee. 
The meta-analysis was done by ﬁ tting Cox proportional 
hazards regression models using all individual patient 
data, and stratifying by trial. Known prognostic factors 
were included as covariates in the model. Repeating the 
meta-analysis by pooling the adjusted estimates from each 
trial (rather than using individual patient data) made little 
diﬀ erence to the combined estimates (data not shown).
Analysis included all randomised patients on an 
intention-to-treat basis. This study is registered as an 
International Standard Randomised Controlled Trial, 
number ISRCTN59368779.
Role of the funding source
The funding sources provided peer-reviewed approval for 
the trial and have had representation (as observers) on 
the Trial Steering Committee, but had no other role in 
the design, conduct, data collection, data analysis or 
interpretation of the study or the results. The 
corresponding author had full access to all the data in the 
study, and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
Between January, 1999, and December, 2002, 
2236 patients were enrolled in START Trial A at 17 centres 
in the UK (ﬁ gure 1). A total of 1129 patients enrolled in 
the quality of life study and 1306 in the photographic 
assessment study (with 878 patients enrolled in both 
substudies).
Demographic and clinical characteristics at 
randomisation were well balanced between treatment 
groups (table 1). Of the women prescribed chemotherapy, 
many (555/793, 70·0%) received an anthracycline-
containing regimen, which was balanced between 
randomised radiotherapy schedules (178/259 [68·7%] for 
50 Gy; 185/264 [70·1%] for 41·6 Gy; and 192/270 [71·1%] 
for 39 Gy). Cyclophosphamide, methotrexate, and 
ﬂ uorouracil combination therapy alone was prescribed 
in 227 women (28·6% of those receiving chemotherapy), 
which was similarly balanced between randomised 
groups (77 [29·7%] for 50 Gy; 78 [29·5%] for 41·6 Gy; and 
72 [26·7%] for 39 Gy). 19 women (six for 50 Gy, nine for 
41·6 Gy, and four for 39 Gy) received an adjuvant taxane. 
Of the 1805 women prescribed tamoxifen or another 
endocrine therapy, most (1790, 99·2%) were continuing 
treatment at randomisation (603/606 [99·5%] for 50 Gy; 
611/618 [98·9%] for 41·6 Gy; and 576/581 [99·1%] for 
39 Gy). 
Data for oestrogen receptor status was not collected as 
part of START Trial A, but routine policy in most of the 
centres during the accrual period was to prescribe 
tamoxifen only to patients who were oestrogen-receptor 
positive or whose oestrogen receptor status was 
unknown. Hence tamoxifen use was a reasonable 
surrogate for oestrogen receptor status in the trial, 
which was balanced between the treatment groups. In 
the quality of life subgroup 21·6% patients underwent 
mastectomy. There were only 29 major treatment 
deviations (including early stopping of treatment, 
patient refusal of allocated treatment, and patients 
found to be ineligible for reasons including presence of 
relapses), resulting in 98·7% compliance with allocated 
treatment (ﬁ gure 1). Compliance with completion of 
quality of life questionnaires over 5 years was more 
than 90%.
Median follow-up of surviving patients was 5·1 years 
(IQR 4·4–6·0), with a maximum follow-up of 8·0 years. At 
the time of analysis, 1881 patients (84·1%) were alive and 
without relapse, 36 (1·6%) were alive with local-regional 
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Figure 2: Kaplan-Meier plot (A) and Nelson-Aalen cumulative hazard plot (B) of local-regional tumour relapse 
in 2236 patients
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relapse (without distant relapse), 54 (2·4%) were alive with 
distant relapse (including 14 with local-regional relapse), 
256 (11·4%) had died (including 43 with local-regional 
relapse), and nine (0·4%) had no follow-up.
At the time of analysis, 93 (4·2%) patients had had 
local-regional tumour relapse, and the hazard ratios relative 
to the 50 Gy group were 1·05 (95% CI 0·63–1·75) after 
41·6 Gy and 1·26 (95% CI 0·77–2·08) after 39 Gy (table 2). 
The estimated absolute diﬀ erences in local-regional relapse 
rates compared with 50 Gy at 5 years were 0·2% (95% CI 
–1·3% to 2·6%) after 41·6 Gy and 0·9% (95% CI 
–0·8% to 3·7%) after 39 Gy. Since the main concern over 
hypofractionation is an excess risk rather than a possible 
beneﬁ t, a more precise estimate of the potential excess risk 
of local-regional relapse was obtained from the upper limit 
of the one-sided 95% CI for the absolute diﬀ erence in 
5-year local-regional relapse rates for each 13-fraction 
schedule compared with 50 Gy. These indicated an 
estimated maximum 2·1% and 3·2% excess risk associated 
with 41·6 Gy and 39 Gy compared with 50 Gy, respectively. 
The Kaplan-Meier and cumulative hazard rate plots for 
local-regional relapse according to fractionation schedule 
(ﬁ gure 2) illustrate the low event rate in all randomised 
groups.
The unadjusted α/β value for local-regional relapse 
estimated from a Cox proportional hazards regression 
model was 4·8 Gy (95% CI 0–16·3). Adjusting for 
prognostic factors resulted in extremely wide conﬁ dence 
limits, since the main eﬀ ects for total dose and total dose x 
dose per fraction were not independently predictive of 
local-regional relapse in the regression model. Hence, the 
α/β value for local-regional relapse was left as a crude 
estimate.
Rates of distant relapse, disease-free survival, and 
overall survival were similar between the fractionation 
schedules, with no evidence of a clinically signiﬁ cant 
detriment for either of the hypofractionated schedules 
compared with 50 Gy (table 2).
Change in breast appearance (photographic) was 
assessed in 1055 patients with both a baseline and at least 
one follow-up image (354 for 50 Gy, 357 for 41·6 Gy, and 
344 for 39 Gy). Not all patients had photographs available 
at both 2 and 5 years, for reasons including the 5-year 
assessment not yet being due at the time of scoring and 
analysis, patient refusal, and withdrawal from the 
photographic study due to relapse. There were no 
associations between score for change in breast appearance 
(photographic) at 2 years or patient demographic or 
treatment characteristics and whether or not the patient 
had a 5-year assessment (data not shown). Mild changes 
were graded for 302 (28·6%) patients and marked changes 
for 32 (3·0%) patients, by 5 years. The hazard ratios for 
any (mild or marked) change in breast appearance 
compared with the 50 Gy group were 1·09 (95% CI 
0·85–1·40, p=0·62) after 41·6 Gy and 0·69 (95% CI 
0·52–0·91, p=0·01) after 39 Gy (ﬁ gures 3 and 4). Figure 3 
shows that the treatment diﬀ erences were evident at 2 years, 
and persisted to 5 years. The α/β estimate for any change 
in breast appearance (photographic) was 3·1 Gy (95% CI 
1·6–4·6) adjusted for age, adjuvant therapy, lymphatic 
radiotherapy, breast size, and surgical deﬁ cit.
Patient quality of life self-assessments of late normal 
tissue eﬀ ects were available for 1080 patients 
(95·7% of all patients in the quality of life study) with a 
baseline and at least one completed follow-up 
questionnaire (359 for 50 Gy, 364 for 41·6 Gy, and 357 for 
39 Gy). Changes in breast appearance and breast hardness 
(breast conserving surgery patients) were the most 
common changes (ﬁ gure 4). According to patient quality 
of life self-assessments of ﬁ ve key normal tissue eﬀ ects 
on the breast or breast area, rates of moderate or marked 
eﬀ ects by 5 years were similar after 41·6 Gy and 50 Gy. 
Rates of moderate or marked normal tissue eﬀ ects tended 
to be lower after 39 Gy than after 50 Gy, with a signiﬁ cantly 
lower rate of change in skin appearance after 39 Gy than 
after 50 Gy (p=0·004). Figure 4 summarises the survival 
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Figure 3: Kaplan-Meier plot of mild/marked change in breast appearance (photographic) in 1055 patients 
with breast conserving surgery
Fractionation schedule Total n=2236 (%)
50 Gy 
n=749
41·6 Gy 
n=750
39 Gy 
n=737 
Ischaemic heart disease*
Reported 12 (1·6) 7 (0·9) 8 (1·1) 27 (1·2)
Conﬁ rmed† [left-sided]‡ 3 (0·4) [1] 2 (0·3) [0] 5 (0·7) [4] 10 (0·4) [5]
Symptomatic rib fracture§
Reported 8 (1·1) 9 (1·2) 10 (1·4) 27 (1·2)
Conﬁ rmed† 1 (0·1) 2 (0·3) 1 (0·1) 4 (0·2)
Symptomatic lung ﬁ brosis
Reported 5 (0·7) 6 (0·8) 7 (0·9) 18 (0·8)
Conﬁ rmed† 0 (0) 2 (0·3) 1 (0·1) 3 (0·1)
Data are n (%). *18 patients had pre-existing heart disease at randomisation and were excluded. †Cases conﬁ rmed 
after imaging and further investigations. ‡Conﬁ rmed cases of ischaemic heart disease in patients with left-sided 
primary tumours. §Reported cases include three with rib fracture after bone metastases and nine after trauma.
Table 3: Incidence of ischaemic heart disease, symptomatic rib fracture, and symptomatic lung ﬁ brosis 
according to fractionation schedule
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analyses of the photographic and patient quality of life 
self-assessments of late normal tissue eﬀ ects for START 
Trial A, showing results generally in favour of the 39 Gy 
group compared with 50 Gy, and similar rates of eﬀ ects 
after 41·6 Gy compared with 50 Gy.
The incidence of ischaemic heart disease, symptomatic 
rib fracture and symptomatic lung ﬁ brosis was low at 
this stage during follow-up, and balanced between the 
schedules (table 3). In the 41·6 Gy group, there was one 
case of pneumonitis 9 months after treatment and one 
patient who developed mild symptoms and signs of 
brachial plexopathy 2 years after treatment. Two patients 
(both 50 Gy in 25 fractions) experienced an unusually 
marked acute skin reaction during their radiotherapy 
treatment, culminating in extensive moist desquamation. 
Neither of these patients had received adjuvant 
chemotherapy. 
There were 26 patients (1·2%) with contralateral breast 
cancer (13 after 50 Gy [1·7%], ﬁ ve after 41·6 Gy [0·7%], 
eight after 39 Gy [1·1%]), and 44 patients (2·0%) had 
other second primary cancers (15 after 50 Gy [0·7%], ten 
after 41·6 Gy [0·4%], 19 after 39 Gy [0·8%]), the most 
frequent being lung (six), ovarian (six), renal (four), and 
colorectal (four). The remaining 24 incidences of second 
primary cancers consisted of one or two cases of several 
diﬀ erent types.
When all patients in the RMH/GOC trial (1410 patients) 
and START Trial A (2236) were included in a meta-analysis, 
the unadjusted estimate of the α/β value for local-regional 
relapse was 4·1 Gy (95% CI 0·9–7·4). Adjusting for 
known prognostic factors (age, chemotherapy, tamoxifen, 
lymphatic radiotherapy, type of primary surgery, boost, 
and pathological tumour size) gave an adjusted α/β value 
for local-regional relapse of 4·6 Gy (95% CI 1·1–8·1). 
Including all the 1202 RMH/GOC trial and 1055 START 
Trial A patients with available photographic assessment 
data in a meta-analysis, the unadjusted estimate of the 
α/β value for any change in breast appearance was 3·6 Gy 
(95% CI 2·4–4·9). Adjusting for age, chemotherapy, 
tamoxifen, breast size, and surgical deﬁ cit gave an 
adjusted α/β value of 3·4 Gy (95% CI 2·3–4·5).
Discussion
The results of START Trial A are consistent with the 
hypothesis that breast cancer is as sensitive to fraction 
size as the normal tissues. The ﬁ rst indication that breast 
cancer could be safely and eﬀ ectively treated using 
fraction sizes above 2·0 Gy was ﬁ rst raised more than 
20 years ago, when biological models were applied to 
retrospective clinical data.24,25 In START Trial A, 41·6 Gy 
in 13 fractions was similar to the control regimen of 
50 Gy in 25 fractions in terms of normal tissue eﬀ ects 
and also in terms of local tumour control.24,25 This result 
is consistent with that of the START Trial B, in which 
40 Gy in 15 fractions over 3 weeks seemed at least as safe 
and eﬀ ective as 50 Gy in 25 fractions. The combined 
trials present mounting evidence that hypofractionation 
is a safe and eﬀ ective approach to breast cancer 
radiotherapy. 
The fractionation sensitivity of breast cancer is 
quantiﬁ ed by an α/β ratio of 4·8 Gy, but the small number 
of local-regional tumour relapse events (N=93) limits 
precision (95% CI 0–16·3 Gy). Statistical power is 
enhanced by considering the results of START Trial A 
together with a larger number of local-regional relapses 
(N=185) recorded by the pilot trial over a 15-year period.8 
A meta-analysis of the pilot data and START Trial A 
generates an α/β ratio for breast cancer of 4·6 Gy (95% CI 
1·1–8·1). The conﬁ dence limits of such an estimate are 
still fairly wide but closer to the estimate of α/β ratio for 
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Figure 4: Forest plot of late normal tissue eﬀ ects assessed as moderate/marked by patients and mild/marked from photographs
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normal tissue eﬀ ects of 3·4 Gy (95% CI 2·3–4·5) from 
the meta-analysis of the photographic assessments. 
Despite the residual imprecision in estimating fraction 
size sensitivity, breast cancer seems to respond diﬀ erently 
to human squamous carcinomas of the bronchus and 
head and neck region, and to experimental animal 
tumours characterised by α/β values of 10 Gy or more.5 
This distinction is important, not only because it has 
potential implications for breast cancer treatment, but 
also because it contributes to accumulating evidence that 
cancers vary in their sensitivity to fraction size.26 The 
molecular mechanisms governing fractionation 
sensitivity are not yet understood, but the cellular 
correlates include recovery from sub-lethal and potentially 
lethal damage.27 The ability to predict fractionation 
sensitivity from the tumour phenotype or genotype might 
allow fraction size to be adjusted more accurately to the 
individual cancer.
The initial estimate of a 10% rate of local-regional 
relapse at 5 years in the 50 Gy control group was based 
on the pilot trial started in 1986. Since then, improvements 
in surgery, radiotherapy techniques, systemic therapy, 
and more eﬀ ective multidisciplinary working have 
reduced risks of both local and metastatic breast cancer 
relapse. The fall in local relapse rates over the years is 
excellent news for patients. While accrual was still 
continuing, the emerging data presented in conﬁ dence 
to the Independent Data Monitoring Committee 
suggested that relapse rates were likely to be lower than 
predicted. At that time, adhering to appropriate 
governance procedures, the potential eﬀ ects of the 
predicted lower than expected relapse rates were 
discussed by the independent Trial Steering Committee 
and the Independent Data Monitoring Committee. The 
consensus from these advisory committees was that 
there was no strong scientiﬁ c rationale for changing the 
protocols and increasing the sample size. Since the 
local-regional relapse rate was lower than expected (<4%), 
the study actually has greater power than originally 
planned to detect a 5% absolute diﬀ erence (97% power, 
assuming 4% in the control group), which represents a 
much larger relative treatment eﬀ ect (4% in control 
group vs 9% in test group compared with 10% vs 15% as 
speciﬁ ed in the protocol). Alternatively, with the lower 
baseline local-regional relapse rate the same sample size 
provides suﬃ  cient power to detect smaller absolute 
diﬀ erences. For example, with a 4% local-regional relapse 
rate in the control group, the study is able to detect an 
absolute diﬀ erence of 3·5% with a similar level (82%) of 
power as originally planned.
The photographic assessments of normal tissue eﬀ ects 
conﬁ rm a dose-response relation between the two test 
doses, from which a precise estimate of α/β value has 
been derived, consistent with previous published work.27 
Assuming a conservative α/β value of 3 Gy for all normal 
tissue eﬀ ects except nerve injury, the 39 Gy and 41·6 Gy 
test doses are equivalent to 46·8 Gy and 51·6 Gy in 2·0 Gy 
equivalents, respectively. The fractionation sensitivity of 
underlying lung tissue or heart might diﬀ er from that of 
ribcage and breast, but this uncertainty is less relevant 
now that the heart can usually be physically shielded 
when advanced techniques of radiotherapy planning and 
delivery are applied.28 The results of patient quality of life 
self-assessments of normal tissue eﬀ ects in START 
Trial A are largely consistent with the dose response 
eﬀ ect seen in the photographic assessments.
Physician assessments of normal tissue eﬀ ects have not 
been presented in this paper. Preliminary analysis of these 
data produce estimates of the relative eﬀ ects of the 
fractionation schedules which seem similar to those 
assessed by the photographic and patient self-assessments. 
Some variation existed, however, between centres in the 
practice used to complete the yearly case report forms. 
Most centres completed these forms in the presence of the 
patient, whereas others completed them afterwards from 
hospital case notes. Since the level of detail included in the 
hospital case notes varied within and between centres, this 
practice, although unbiased between treatment groups, 
could have led to underreporting of physician-assessed 
normal tissue eﬀ ects. The results of the physician 
assessments will thus be the subject of a separate paper, 
reporting also the sensitivity of the endpoints according to 
method of completion of case report forms.
The 11·5% absolute diﬀ erence in breast appearance at 
5 years between the two test regimens generates a γ value 
of 1·4 at the steepest part of the dose-response curve (the 
γ value measures the gradient of the dose response curve 
as the percent increase in eﬀ ect per percent increase in 
total dose delivered in 2·0 Gy fractions29), which converts 
into a 5·2% absolute increase in normal tissue eﬀ ects per 
2·0 Gy fraction. The local-regional relapse data from 
START Trial A generate a γ value of 0·2, which gives some 
indication of the small gains expected from dose escalation 
when tumour control is more than 95%.30 This ﬁ nding 
has implications for modelling the imprecision in the 
estimate of breast cancer fractionation sensitivity. Taking 
into account the higher 10-year local-regional relapse rates 
in the RMH/GOC pilot trial, the current precision of the 
α/β estimate can be shown by estimating a 95% CI for the 
10-year local-regional relapse rate of a speciﬁ c fractionation 
schedule. If the α/β value for tumour control is as high as 
8·1 Gy (the upper 95% conﬁ dence limit), a 13-fraction 
regimen matched to 50 Gy in 25 fractions for late normal 
tissue eﬀ ects would have an anti-tumour eﬀ ect equivalent 
to 47·3 Gy in 2·0 Gy fractions, accounting for 1·5% more 
local-regional relapses compared with 50 Gy in 25 fractions. 
If the α/β value for tumour control is as low as 1·1 Gy (the 
lower 95% conﬁ dence limit), the same schedule would be 
responsible for 4·3% fewer local-regional relapses at 
10 years compared with 50 Gy in 25 fractions. With the 
lower 5-year local-regional relapse rates in START (3–4%) 
compared with the RMH/GOC pilot trial (8%), the 
absolute excess local-regional is roughly half in the START 
patient population.
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A median follow-up of 5 years is too short to allow 
assessment of all the potential late normal tissue eﬀ ects 
such as cardiac damage. Follow-up of all women within 
the trial is continuing in order to assess the long-term 
eﬀ ects of the fractionation schedules. However, the 
RMH/GOC pilot data (median follow-up 10 years) showed 
that the relative eﬀ ects of diﬀ erent fractionation schedules 
remain unchanged over time. 15–20 years of follow-up 
will be needed to reliably measure cardiac eﬀ ects. The 
short-term priority is to protect the heart from exposure 
to radiotherapy; something that is now possible with 
advanced radiotherapy technologies.
In conclusion, our data are consistent with the 
hypothesis that breast cancer shows similar responsiveness 
to fraction size as the late responding normal tissues of 
the breast, as indicated by the α/β estimates. A 13-fraction 
regimen is unlikely to represent the limits of 
hypofractionation. The ongoing NCRN FAST Trial is 
testing ﬁ ve fractions of 5·7 Gy and 6·0 Gy, treating one 
fraction per week, with a long-term aim to reduce overall 
treatment time, not just for convenience to patients, but 
to minimise the potential eﬀ ect of rapid tumour growth 
during radiotherapy.
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(Cheltenham General Hospital), S Simmons (ICR-CTSU, Sutton), 
G Sumo (ICR-CTSU, Sutton), M A Sydenham (ICR-CTSU, Sutton), 
K Venables (Mount Vernon Hospital, Northwood), and J R Yarnold 
(Chair and Chief Investigator, Institute of Cancer Research, Royal 
Marsden NHS Foundation Trust).
The START Trialists’ Group
In addition to the Trial Management Group (named as Writing 
Committee above), the following groups are all part of the START 
collaboration:
Principal and main co-investigators according to centre (number of patients 
recruited): Belfast City Hospital, Belfast (261), W P Abram, Ayr, J Clarke, 
J J A McAleer; Bristol Haematology and Oncology Centre, Bristol (26), 
J D Graham, P Riddle, S Goodman, M Tomlinson; Cheltenham General 
Hospital, Cheltenham (308), K Benstead R Counsell, S A G Elyan, 
J R Owen; Churchill Hospital, Oxford (17), B Lavery, E Sugden; Guys and 
St Thomas’ NHS Trust, London (17), J Dobbs; King Edward VII Hospital, 
Midhurst (5), S Whittaker; New Cross Hospital, Wolverhampton (17), 
C Brammer, M Churn; Ninewells Hospital, Dundee (173), 
D J A Adamson, J A Dewar; Nottingham University Hospital NHS Trust 
(137), D A L Morgan; Royal Berkshire NHS Foundation Trust, Reading 
(236), J M Barrett, C D A Charlton; Royal Devon and Exeter Foundation 
Trust, Exeter (32), P Bliss, A Goodman, A Holmes, A Hong; Royal 
Marsden NHS Foundation Trust, Sutton (417), A Neal, G Ross, 
A Rostom, D Tait, J R Yarnold; Royal Marsden NHS Foundation Trust, 
London (40), G Ross; Royal Surrey County Hospital, Guildford (314), 
Foulkes, M Illsley, R Laing, A Neal, Thomas, C Topham, S Whittaker; 
Southend Hospital, Southend (11), Koreich, C Trask; Torbay Hospital, 
Torquay (18), P Bliss, A G Goodman; Velindre Hospital NHS Trust, 
Cardiﬀ  (207), P J Barrett-Lee, T D L Crosby, C C Gaﬀ ney, T W O Tilsley.
Trial Steering Committee: Independent members: A Barrett (Chair, 
University of East Anglia), M Armitage (Royal Bournemouth & 
Christchurch NHS Trust), S M Bentzen (University of Wisconsin 
Medical School, Madison, USA), U Chetty (Western General Hospital, 
Edinburgh), P Mayles (Clatterbridge Centre for Oncology, Wirral), 
L Walker (University of Hull). 
Independent Data Monitoring Committee: H Lucraft (Chair, Newcastle 
General Hospital), M Parmar (MRC Clinical Trials Unit, London), 
I Turesson (Akadamiska Sjukhuset, Uppsala, Sweden).
Consumers (observers to Trial Management Group): M Carling (RAGE), 
J Pritchard (independent), M King (ex-member of RAGE, deceased), 
E Parkin (ex-member of RAGE).
Funders (observers to Trial Steering Committee): K Law (Cancer Research 
UK), S Perkins (Medical Research Council), U Wells (Department of 
Health).
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